Analyst Research

Qumu Corporation (NASDAQ:QUMU) Current Deferred Revenue At $10.413 Millions

For the year concluded 2015-12-31, Qumu Corporation (NASDAQ:QUMU) posted comprehensive income of $-1.521 millions. It was $-1.521 millions for the quarter settled 2015-12-31. Consolidated net income/loss was $-28.699 millions for the fiscal closed 2015-12-31. For the quarter closed 2015-12-31 it was $-28.699 millions. Cost of goods sold For the year […]

January 10, 2017 ·

Intermolecular, Inc. (NASDAQ:IMI) Current Deferred Revenue At $2.595 Millions

For the year concluded 2015-12-31, Intermolecular, Inc. (NASDAQ:IMI) posted comprehensive income of $-0.024 millions. It was $-0.024 millions for the quarter settled 2015-12-31. Consolidated net income/loss was $-21.013 millions for the fiscal closed 2015-12-31. For the quarter closed 2015-12-31 it was $-21.013 millions. Cost of goods sold For the year […]

January 10, 2017 ·

Insys Therapeutics, Inc. (NASDAQ:INSY) Current Deferred Revenue At $5.307 Millions

For the year concluded 2012-12-31, Insys Therapeutics, Inc. (NASDAQ:INSY) posted comprehensive income of $-0.152 millions. It was $-0.152 millions for the quarter settled 2012-12-31. Consolidated net income/loss was $58.476 millions for the fiscal closed 2012-12-31. For the quarter closed 2012-12-31 it was $58.476 millions. Cost of goods sold For the […]

January 10, 2017 ·

Amicus Therapeutics, Inc. (NASDAQ:FOLD) Current Deferred Revenue At $8.504 Millions

For the year concluded 2011-12-31, Amicus Therapeutics, Inc. (NASDAQ:FOLD) posted comprehensive income of $-0.115 millions. It was $-0.115 millions for the quarter settled 2011-12-31. Consolidated net income/loss was $-132.118 millions for the fiscal closed 2011-12-31. For the quarter closed 2011-12-31 it was $-132.118 millions. Cost of goods sold For the […]

January 10, 2017 ·

Crossroads Systems, Inc. (NASDAQ:CRDS) Current Deferred Revenue At $7.234 Millions

For the year concluded 2015-10-31, Crossroads Systems, Inc. (NASDAQ:CRDS) posted comprehensive income of $-0.09 millions. It was $-0.09 millions for the quarter settled 2015-10-31. Consolidated net income/loss was $-9.044 millions for the fiscal closed 2015-10-31. For the quarter closed 2015-10-31 it was $-9.044 millions. Cost of goods sold For the […]

January 10, 2017 ·

Omnicell, Inc. (NASDAQ:OMCL) Current Deferred Revenue At $53.656 Millions

For the year concluded 2015-12-31, Omnicell, Inc. (NASDAQ:OMCL) posted comprehensive income of $-2.73 millions. It was $-2.73 millions for the quarter settled 2015-12-31. Consolidated net income/loss was $30.76 millions for the fiscal closed 2015-12-31. For the quarter closed 2015-12-31 it was $30.76 millions. Cost of goods sold For the year […]

January 10, 2017 ·